Cantor Fitzgerald Starts Agile Therapeutics (AGRX) at Buy

Cantor Fitzgerald initiated coverage on Agile Therapeutics (NASDAQ: AGRX) with a Buy rating and a price target of $17.00.

Analyst Irina Rivkind Koffler said, "Agile is developing Twirla, a Phase III, low-dose estrogen contraceptive patch that we believe has the potential to approximate the Ortho Evra launch trajectory. We expect positive data from the Phase III trial in mid-2015, followed by product launch in early 2017. Even under conservative risk-adjusted assumptions we believe that Twirla can attain over $300M in peak sales, and we think that this opportunity makes Agile an attractive, late-stage take-out target to a larger company focused on women's health. We see the stock as undervalued following the caution and recent sell-off in the biotech sector and initiate coverage with a BUY rating and $17 PT."

For an analyst ratings summary and ratings history on Agile Therapeutics click here. For more ratings news on Agile Therapeutics click here.

Shares of Agile Therapeutics closed at $6.78 yesterday.

You May Also Be Interested In

• Truist Securities Starts Vishay Intertechnology (VSH) at Buy
• Morgan Stanley Starts Banca Mediolanum SpA (BMED:IM) at Equalweight
• Morgan Stanley Resumes Euronext NV (ENX:FP) (EUXTF) at Overweight